Ga-HBED-iPSMA PET with CT or MRI for Prostate Cancer

Phase-Based Progress Estimates
Prostate Cancer+2 More
MRI - DiagnosticTest
What conditions do you have?

Study Summary

This trial is testing a new imaging agent to see if it can better detect prostate cancer, especially when PSA levels are low.

Eligible Conditions
  • Prostate Cancer
  • Adenocarcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 2 years

2 years
Disease localization by PSMA PET/MR
Incidence of Treatment-Emergent Adverse Events assessed by common terminology criteria for adverse events (CTCAE v4.0)
PSA relapse free survival in patients undergoing PSMA PET/MR guided SRT

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Active Control

1171 Total Participants · 2 Treatment Groups

Primary Treatment: Ga-HBED-iPSMA PET with CT or MRI · No Placebo Group · Phase 2

Ga-HBED-iPSMA PET with CT or MRIActiveComparator Group · 3 Interventions: MRI, Ga-HBED-iPSMA PET, PET/CT · Intervention Types: DiagnosticTest, Drug, DiagnosticTest
Ga-HBED-iPSMA PET with MRIActiveComparator Group · 2 Interventions: MRI, Ga-HBED-iPSMA PET · Intervention Types: DiagnosticTest, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,823 Previous Clinical Trials
583,313 Total Patients Enrolled
127 Trials studying Prostate Cancer
64,255 Patients Enrolled for Prostate Cancer
Heiko Schöder, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
5 Previous Clinical Trials
104 Total Patients Enrolled
1 Trials studying Prostate Cancer
20 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patient must be able to tolerate PET/CT or PET/MR imaging.
You have a PSA level of 2 ng/ml or more above the most recent therapy nadir.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.